Immediate test results and patient treatment reduces the likelihood of a readmission “within 30 days of discharge” that could result in hospital penalties under Accountable Care.
“Consolidates and replaces a suitcase full of readers with a single device, that adapts to existing and FDA Cleared Point of Care tests, eliminates transportation of patient samples to central labs by testing the patient wherever they are, and transmits test results directly to The Cloud. The device that finally makes Point of Care diagnostics practical for healthcare providers."
Hello, I am reaching out to our investors and future investors to invite you to a Zoom Webinar to share more details about our new and exciting SimpleTest™ product ( www.WeFunder.com/iAssay ) that is completely revolutionizing the medical testing industry. Here are the details for the Webinar: When: Mar 2, 2021 12:00 PM Eastern Time […]
Dear investors, I am pleased to share some exciting news with you…We are no longer pre-revenue! GattaCo, makers of next generation medical diagnostics and simplified sample collection and processing, has signed a Memorandum of Understanding (MOU) with iAssay enabling engineers and scientists to work together to integrate and optimize their products to provide accurate, enhanced […]
During the week of January 11, 2021, JP Morgan conducted their annual healthcare conference. Having attended for several years we wanted to provide a few relevant highlights for our investors. As a consequence of the COVID-19 pandemic there has been an increased acceptance in the use of point of care testing to determine who has […]
iAssay is honored to have been included in this All Things Technology issue, Industry News Spotlight. See it here: https://lnkd.in/gXtBYU3
Murrieta / San Diego— 11/10/2020 — Today GattaCo and iAssay announced that they have signed a Memorandum of Understanding (MOU), enabling engineers and scientists to work together to integrate and optimize their products in an effort to provide enhanced rapid serology testing, including COVID-19 antibody testing and electronic test result transmission to federal and state […]
We are excited to share the stage with so many top talents in the innovation space. The patented iAssay® System is a handheld medical test reader. It is agnostic to test type, and features an expandable test menu for testing patients at point of care using a fingerstick blood sample or urine sample. Flexibility by […]
iAssay automatically sends COVID-19 test results to the Cloud! This has always been a part of the plan because of its anticipated importance. Now that HHS has mandated that COVID-19 test results be sent to them periodically, iAssay will have you covered! Comply with us! Courtesy of Patricia Jones, PhD and The AACC On September […]
The USPTO granted iAssay US Patent 10,753,921 on August 25, 2020. This is the Continuation in Part (CIP) of US Patent 10,309,954 granted in June, 2019. Another exciting CIP application was filed the day before the latest patent granted on August 24, 2020.
San Diego – Sept 1, 2020 Dr. Edward Strong, the geneticist who co-founded and served as CEO of MedGenomics, Inc., has been named Scientific Director of iAssay, Inc. Strong will guide the researchers and engineers who are developing iAssay’s product line. iAssay is creating a suite of tools that support remote testing for COVID-19 and other […]